Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manoj Chelvanambi

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Nature|September 5, 2025
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2025
Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunitiesAnne Knisely, Yibo Dai, Graham L Barlow, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature|June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.
Nature|January 10, 2023
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.
Nature Medicine|November 14, 2025
Microbial signals in primary and metastatic brain tumorsGolnaz Morad, Ashish V Damania, Brenda Melendez, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Nature|September 5, 2025
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2025
Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunitiesAnne Knisely, Yibo Dai, Graham L Barlow, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature|June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.
Nature|January 10, 2023
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapyChristopher P Vellano, Michael G White, Miles C Andrews, et al.
Nature Medicine|November 14, 2025
Microbial signals in primary and metastatic brain tumorsGolnaz Morad, Ashish V Damania, Brenda Melendez, et al.
Pageof 3